A retrospective cohort study of polatuzumab vedotin combined with immunochemotherapy in Chinese patients with relapse/refractory diffuse large B cell lymphoma

BACKGROUND: There are no standard therapies for patients with relapse/refractory diffuse large B-cell lymphoma (R/R DLBCL) who are ineligible for transplantation. Recently, polatuzumab vedotin (pola) combined with rituximab and bendamustine (pola-BR) has been validated in clinical trials. However, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yanyan, Wuxiao, Zhijun, Kong, Fancong, Feng, Jifeng, Wu, Jianqiu, Yao, Zhihua, Zhou, Weilun, Li, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622495/
https://www.ncbi.nlm.nih.gov/pubmed/36330404
http://dx.doi.org/10.21037/atm-22-4593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622495/
https://www.ncbi.nlm.nih.gov/pubmed/36330404
http://dx.doi.org/10.21037/atm-22-4593

Ejemplares similares